乳腺癌手术后放疗后进行卵巢照射及泼尼松治疗。
Ovarian irradiation and prednisone therapy following surgery and radiotherapy for carcinoma of the breast.
作者信息
Meakin J W, Allt W E, Beale F A, Brown T C, Bush R S, Clark R M, Fitzpatrick P J, Hawkins N V, Jenkin R D, Pringle J F, Reid J G, Rider W D, Hayward J L, Bulbrook R D
出版信息
Can Med Assoc J. 1979 May 19;120(10):1221-9.
Following mastectomy, patients with operable breast cancer underwent postoperative irradiation of the chest wall and regional lymph nodes. They were then assigned at random to receive no further therapy, ovarian irradiation (2000 rads in 5 days) or ovarian irradiation in the same dosage plus prednisone, 7.5 mg daily. A total of 705 patients received the randomly assigned treatment and were followed for up to 10 years. In premenopausal patients who received ovarian irradiation the recurrence of breast cancer was delayed and survival prolonged, but not significantly. In premenopausal women aged 45 years or more ovarian irradiation plus prednisone therapy significantly delayed the recurrence of breast cancer (P = 0.02) and prolonged survival (P = 0.02); the survival expectancy of these patients was similar to that of the general population of the same age from the third year after the cancer operation. No value was demonstrated for ovarian irradiation with or without prednisone therapy in postmenopausal patients.
乳房切除术后，可手术切除的乳腺癌患者接受了胸壁和区域淋巴结的术后放疗。然后，他们被随机分配接受以下治疗：不再接受进一步治疗、卵巢放疗（5天内照射2000拉德）或相同剂量的卵巢放疗加泼尼松，每日7.5毫克。共有705名患者接受了随机分配的治疗，并随访了长达10年。在接受卵巢放疗的绝经前患者中，乳腺癌的复发得到延迟，生存期延长，但差异不显著。在45岁及以上的绝经前女性中，卵巢放疗加泼尼松治疗显著延迟了乳腺癌的复发（P = 0.02）并延长了生存期（P = 0.02）；这些患者的预期生存期与癌症手术后第三年同年龄的普通人群相似。对于绝经后患者，无论是否使用泼尼松治疗，卵巢放疗均未显示出价值。
Zotero 插件